Kineta Gross Margin 2014-2024 | KANT
Current and historical gross margin for Kineta (KANT) over the last 10 years. The current gross profit margin for Kineta as of June 30, 2024 is %.
Kineta Gross Margin Historical Data |
Date |
TTM Revenue |
TTM Gross Profit |
Gross Margin |
2023-12-31 |
$0.01B |
$0.01B |
100.00% |
2023-06-30 |
$0.01B |
$0.01B |
100.00% |
2023-03-31 |
$0.00B |
$0.00B |
100.00% |
2022-12-31 |
$0.00B |
$0.00B |
100.00% |
2022-09-30 |
$0.00B |
$0.00B |
100.00% |
2022-06-30 |
$0.01B |
$0.01B |
100.00% |
2022-03-31 |
$0.01B |
$0.01B |
100.00% |
2021-12-31 |
$0.01B |
$0.01B |
100.00% |
2021-09-30 |
$0.01B |
$0.01B |
100.00% |
2021-06-30 |
$0.01B |
$0.01B |
100.00% |
2019-03-31 |
$0.01B |
$0.01B |
100.00% |
2018-09-30 |
$0.01B |
$0.01B |
100.00% |
2018-06-30 |
$0.01B |
$0.01B |
100.00% |
2018-03-31 |
$0.01B |
$0.01B |
100.00% |
2017-12-31 |
$0.01B |
$0.01B |
100.00% |
2017-09-30 |
$0.01B |
$0.01B |
100.00% |
2017-06-30 |
$0.01B |
$0.01B |
100.00% |
2017-03-31 |
$0.01B |
$0.01B |
100.00% |
2016-12-31 |
$0.01B |
$0.01B |
100.00% |
2016-09-30 |
$0.01B |
$0.01B |
100.00% |
2016-06-30 |
$0.00B |
$0.00B |
100.00% |
2016-03-31 |
$0.00B |
$0.00B |
100.00% |
2015-12-31 |
$0.00B |
$0.00B |
100.00% |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
MED-BIOMED/GENE |
$0.000B |
$0.005B |
Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based in Seattle.
|